Emmy Boerrigter

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts et al. · Nature Communications · 2024 · 120 citations · Full text

Medicine, Biostatistics, Oncology +17

Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Sofie H. Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi et al. · Clinical Cancer Research · 2023 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study

Guillemette E. Benoist, Inge M. van Oort, Emmy Boerrigter et al. · Clinical Chemistry · 2020 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment

Emmy Boerrigter, Guillemette E. Benoist, Inge M. van Oort et al. · Molecular Oncology · 2021 · 19 citations · Full text

Medicine, Molecular Biology, Oncology +17

A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer

Emmy Boerrigter, Joanneke K. Overbeek, Guillemette E. Benoist et al. · European Urology Oncology · 2024 · 10 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14